Our pipeline

Pipeline

Our R&D strategy leverages our validated technology platform with a focus on expanding beyond our existing core expertise in COVID-19, influenza, and COVID-19-Influenza Combination (CIC) vaccines.

We are identifying early-stage pipeline and innovation expansion opportunities to support long-term growth. Early work will include strategically moving forward with RSV and pandemic flu, which are disease areas that leverage our existing experience and internal expertise in infectious diseases. Our next step is to identify other infectious disease areas that are or could become vaccine-preventable, meet other guiding principles, and for which our technology could possess differentiating attributes. Finally, we will potentially expand more broadly beyond infectious diseases, by leveraging specialized scientific knowledge and robust translational models to evaluate a range of chronic diseases where our technology could lead to the development of preclinical constructs to advance to proof of mechanism and proof of concept studies, and beyond.  
 

Our pipeline

Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.

Our Matrix-M adjuvant technology

Matrix-M adjuvant

The vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.

Vaccines in Novavax Pipeline and Status
Therapeutic area
Candidate
Phase of trial
Authorized Use
Partner
  
Preclinical
Phase 1
Phase 2
Phase 3
  
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine
    
 
Authorized1
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
   
 
Phase 3
Novavax led
Respiratory diseases
Seasonal influenza
Influenza vaccine (Older Adults)
   
 
Phase 3
Novavax led
Respiratory diseases
Respiratory syncytial virus (RSV)
RSV Combinations
 
Preclinical
   
Novavax led
Respiratory diseases
Pandemic Influenza
Influenza
 
Preclinical
   
Novavax led
Developed by partners leveraging Novavax technology
Parasitic diseases
Malaria
R21/Matrix-MTM adjuvant
    
 
Authorized2
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine
 
Authorized1
Partner
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
 
Phase 3
Partner
Novavax led
Respiratory diseases
Seasonal influenza
Influenza vaccine (Older Adults)
 
Phase 3
Partner
Novavax led
Respiratory diseases
Respiratory syncytial virus (RSV)
RSV Combinations
 
Preclinical
Partner
Novavax led
Respiratory diseases
Pandemic Influenza
Influenza
 
Preclinical
Partner
Novavax led
Developed by partners leveraging Novavax technology
Parasitic diseases
Malaria
R21/Matrix-MTM adjuvant
 
Authorized2
Partner

Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax™; and Nuvaxovid™. Authorization information can be found by country at https://novavaxcovidvaccine.com.


2 Commercialized by Serum Institute of India and granted prequalification by the WHO and distributed by UNICEF to endemic countries in Africa.

What we do

Driving value through targeted innovation with our validated technology

Who we are

Novavax is powered by global collaborations